Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: A 1-year, randomized, double-blind, placebo-controlled study

Diabetes Care

Volumn 36, Issue 2, 2013, Pages 237-244

  McGill, Janet B ^a   Sloan, Lance ^b   Newman, Jennifer ^c   Patel, Sanjay ^d   Sauce, Christophe ^e   Von Eynatten, Maximilian ^f   Woerle, Hans Juergen ^f  

^a WASHINGTON UNIVERSITY   (United States)

^b Texas Institute for Kidney and Endocrine Disorders   (United States)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d BOEHRINGER INGELHEIM LTD   (United Kingdom)

^e BOEHRINGER INGELHEIM   (France)

^f BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; LINAGLIPTIN; ORAL ANTIDIABETIC AGENT; PLACEBO; SULFONYLUREA;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; CEREBROVASCULAR ACCIDENT; CONSTIPATION; CONTROLLED STUDY; COUGHING; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FALLING; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART DEATH; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPOGLYCEMIA; INFLUENZA; KIDNEY FAILURE; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MUSCLE SPASM; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK FACTOR; SIDE EFFECT; UNSTABLE ANGINA PECTORIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WEIGHT CHANGE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; MALE; MIDDLE AGED; PURINES; QUINAZOLINES; RENAL INSUFFICIENCY; YOUNG ADULT;

EID: 84873864348     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-0706     Document Type: Article

References (37)

1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311-321
2. Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant 2005;20:2587-2593
3. Atkins RC. The epidemiology of chronic kidney disease. Kidney Int Suppl 2005; 94:S14-S18
4. Molitch ME, DeFronzo RA, Franz MJ, et al.; American Diabetes Association. Nephropathy in diabetes. Diabetes Care 2004;27(Suppl. 1):S79-S83
5. American Diabetes Association. Economic costs of diabetes in the U.S. In 2007. Diabetes Care 2008;31:596-615
6. Khuwaja AK, Khowaja LA, Cosgrove P. The economic costs of diabetes in developing countries: some concerns and recommendations. Diabetologia 2010;53: 389-390; author reply 391-392
7. American Diabetes Association. Standards of medical carein diabetesd2011. Diabetes Care 2011;34(Suppl. 1):S11-S61
8. Bakris GL. Recognition, pathogenesis, and treatment of different stagesofnephropathy in patients with type 2 diabetes mellitus. Mayo Clin Proc 2011;86:444-456
9. Shrishrimal K, Hart P, Michota F. Managing diabetes in hemodialysis patients: observations and recommendations. Cleve Clin J Med 2009;76:649-655
10. Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, lina-gliptin, in humans. Drug Metab Dispos 2010;38:667-678
11. Heise T, Graefe-Mody EU, Huttner S, Ring A, Trommeshauser D, Dugi KA. Pharma-cokinetics, pharmacodynamics and tolera-bility of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab 2009;11:786-794
12. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011;13:7-18
13. Deacon CF, Holst JJ. Linagliptin, axanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2010;19:133-140
14. Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the phar-macokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011;13:939-946
15. Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle H-J, DugiKA.Effect of linagliptin monotherapy on glycaemic control and markers of b-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011;13:258-267
16. Forst T, Uhlig-Laske B, Ring A, Ritzhaupt A, Graefe-Mody U, Dugi KA. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011;13:542-550
17. Kawamori R, Inagaki N, Araki E, et al. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes Metab 2012;14:348-357
18. Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2diabetes: arandomized, doubleblind, placebo-controlled study. Diabetes Obes Metab 2011;13:65-74
19. Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med 2011;28:1352-1361
20. Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011;13:653-661
21. Schernthaner G, Barnett AH, Emser A, et al. Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus. Diabetes Obes Metab 2012;14:470-478
22. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005;28:1245-1249
23. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352: 854-865
24. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837-853
25. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117
26. Chapelsky MC, Thompson-Culkin K, Miller AK, Sack M, Blum R, Freed MI. Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency. J Clin Pharmacol 2003;43: 252-259
27. Kothny W, Shao Q, Groop PH, Lukashevich V. One-year safety, tolerabil-ity and efficacy of vildagliptin in patients with type2 diabetes and moderate or severe renal insufficiency. Diabetes Obes Metab. 12 June 2012. [Epub ahead of print]
28. Nowicki M, Rychlik I, Haller H, Warren ML, Suchower L, Gause-Nilsson I; D1680C00007 Investigators. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab 2011;13:523-532
29. Nowicki M, Rychlik I, Haller H, et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract 2011;65:1230-1239
30. Chan JCN, Scott R, Arjona Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008;10:545-555
31. Meyers JL, Candrilli SD, Kovacs B. Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment. Postgrad Med 2011;123:133-143
32. 1c). Diabetes Care 2003;26:881-885
33. Friedrich C, Emser A, Woerle H-J, Graefe-Mody U. Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes. Am J Ther. In press
34. Ritz E. Limitations and future treatment options in type 2 diabetes with renal impairment. Diabetes Care 2011;34(Suppl. 2):S330-S334
35. Drucker DJ, Goldfine AB. Cardiovascular safety and diabetes drug development. Lancet 2011;377:977-979
36. Verge D, López X. Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes. Curr Diabetes Rev 2010;6:191-200
37. Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle H-J. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol 2012;11:3